NRx Pharmaceuticals received a positive Discipline Review Letter from the FDA Office of Generic Drugs on April 22, 2026, confirming that its preservative‑free ketamine ANDA meets all quality and manufacturing requirements. The letter, which covers drug substance, drug product, manufacturing and microbiology, requires only minor administrative updates and stability data revisions.
The FDA’s review is part of the current approval cycle and signals that the company can expect a commercial launch of the preservative‑free ketamine product in summer 2026. The approval removes the need for the benzethonium chloride preservative that is no longer permitted in new drugs, addressing safety concerns and potential supply shortages in the generic ketamine market, which is estimated at $750 million worldwide.
Financially, NRx has been improving its operating profile. In Q1 2025 the company reported a net loss of $5.5 million, better than the $6.5 million loss in Q1 2024, and a loss from operations of $16.2 million versus $18.5 million in 2024. The company ended 2025 with $7.8 million in cash and expects to continue operations through 2026, with clinic revenue growth and cost reductions supporting a projected 67 % revenue increase for fiscal 2026 and a path to profitability that year.
"Every 11 minutes an American dies from suicide. Every day we lose 20 or more Veterans and Soldiers, along with countless first responders," said Dr. Jonathan C. Javitt, NRx’s CEO and Chairman. "We deeply appreciate the FDA’s timely review of the proposed labeling for our generic drug application and look forward to an ongoing collaborative relationship," he added.
The positive review de‑risks the company’s first revenue‑generating product and positions NRx to capitalize on a growing market for ketamine treatments for depression and suicidality. The FDA’s support, coupled with a Presidential Executive Order issued on April 16, 2026 that prioritizes rapid approval of psychedelic drugs for mental health conditions, creates a favorable regulatory environment for NRx’s pipeline. While the company continues to face financial challenges, the regulatory milestone and improving financial metrics suggest a strengthening trajectory for the business.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.